EORTC presents at ASCO Annual Meeting 2018 in Chicago
30 May 2018
In a few days’ time, the ASCO Annual Meeting will take place in Chicago, USA (1-5 June 2018).
“This year’s theme “Delivering discoveries: expanding the reach of precision medicine” focuses on making precision medicine a reality by driving progress and expanding its reach so that every patient can have the opportunity to benefit,” Dr. Bruce Johnson, ASCO President.
EORTC will present the results of several studies:
Oral presentations
- Fifteen-year results of the randomised EORTC trial 22922/10925 investigating internal mammary and medial supraclavicular (IM-MS) lymph node irradiation in stage I-III breast cancer. (Abstract 504)
Oral Abstract Session: Breast Cancer – Local/Regional/Adjuvant
Time: Monday, June 4, 2018, 8:00 AM – 11:00 AM
Authors: Philip Poortmans, Sandra Collette, Henk Struikmans, Karin De Winter, Erik Van Limbergen, Carine Kirkove, Volker Budach, Karine Peignaux-Casasnovas, Ernest Vonk, Desiree van den Bongard, Sofia Rivera, Daniel Zips, Geertjan Van Tienhoven, Matthias Guckenberger, Roxolyana Abdah-Bortnyak, Alain Fourquet, Harry G. M. Bartelink
- Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine +/- oxaliplatin in locally advanced rectal cancer: Final results of PETACC-6. (Abstract 3500)
Oral abstract Session: Gastrointestinal Cancer
Time: Tuesday, June 5, 2018, 9:45 AM – 12:45 PM
Authors: Hans-Joachim Schmoll, Karin Haustermans, Timothy Jay Price, Bernard Nordlinger, Ralf Hofheinz, Jean-Francois Daisne, Jaak Janssens, Baruch Brenner, Peter Schmidt, Hans Reinel, Stephan Hollerbach, Karel Caca, Florian W.B. Fauth, Carla Hannig, John Raymond Zalcberg, Niall C. Tebbutt, Murielle E. Mauer, Sandrine Marreaud, Manfred P. Lutz, Eric Van Cutsem
Poster presentations
- Activity and safety of crizotinib in patients with advanced, metastatic alveolar soft part sarcoma (ASPS) with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 CREATE. (Abstract 11540)
Poster Session: Sarcoma
Time: Saturday, June 2, 2018 – 8:00 – 11:30 AM
Authors: Patrick Schöffski, Agnieszka Wozniak, Bernd Kasper, Steinar Aamdal, Michael Gordon Leahy, Piotr Rutkowski, Sebastian Bauer, Hans Gelderblom, Antoine Italiano, Lars H Lindner, Ivo M. Hennig, Sandra J. Strauss, Branko Zakotnik, Alan Anthoney, Birgit Geoerger, Jean-Yves Blay, Peter Reichardt, Winette TA van der Graaf, Sandrine Marreaud, Silvia Stacchiotti
- Doxorubicin plus dacarbazine (DoDa), doxorubicin plus ifosfamide (DI) or doxorubicin alone (Do) as first line treatment for advanced leiomyosarcoma (LMS): A retrospective study from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG). (Abstract 11574)
Poster Session: Sarcoma
Time: Saturday, June 2, 2018 – 8:00 – 11:30 AM
Authors: Lorenzo D’Ambrosio, Nathan Touati, Jean-Yves Blay, Giovanni Grignani, Ronan Flippot, Anna Malgorzata Czarnecka, Sophie Piperno-Neumann, Javier Martin Broto, Roberta Sanfilippo, Daniela Katz, Florence Duffaud, Bruno Vincenzi, Bernd Kasper, Daniel P. Stark, Filomena Mazzeo, Armin Tuchscherer, Saskia Litiere, Ward Sents, Hans Gelderblom, Alessandro Gronchi, on behalf of the EORTC STBSG
- BEST OF: A phase III study assessing the best of radiotherapy (Intensity Modulated RadioTherapy, IMRT) compared to the best of surgery (Trans-Oral Surgery, TOS) in patients with T1-T2, N0 oropharyngeal squamous cell carcinoma (OPSCC). (Abstract TPS6098)
Poster Session: Head and Neck Cancer
Time: Saturday, June 2, 2018, 1:15 – 4:45 PM
Authors: Christian Simon, Carmela Aves Caballero, Catherine Fortpied, Mererid Evans, Petri Koivunen, Jean-Jacques Stelmes, Maria Urbanowicz, Jean Bourhis, Frank Zimmermann, Jens Peter Klussmann, Andreas Dietz, Giuseppe Spriano, C. Rene Leemans, Susanne Singer, Inge Tinhofer, Joanne Patterson, Silvana Quaglini, Keith Hunter, Vincent Gregoire
- Hope for salivary gland cancer (SGC): EORTC HNCG/UKCRN 1206 randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) inpatients with recurrent and/or metastatic androgen receptor (AR) expressing SGC (NCT01969578). (Abstract TPS6099)
Poster Session: Head and Neck Cancer
Time: Saturday, June 2, 2018, 1:15 – 4:45 PM
Authors: Laura Locati, Carmela Aves Caballero, Catherine Fortpied, Federica Perrone, Pasquale Quattrone, Kevin Harrington, Vincent Gregoire, Lisa F. Licitra
- EORTC 1559-HNCG: A pilot study of personalized biomarker-based treatment strategy or immunotherapy in patients with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN)—”UPSTREAM”. (Abstract TPS6095)
Poster Session: Head and Neck Cancer
Time: Saturday, June 2, 2018, 1:15 – 4:45 PM
Authors: Rachel Galot, Lisa F. Licitra, Christophe Le Tourneau, Joel Guigay, Inge Tinhofer, Anthony Hee Kong, Carmela Aves Caballero, Catherine Fortpied, Anne-Sophie Govaerts, Dominiek Staelens, Tiana Raveloarivahy, Jean-Francois Laes, Jean-Luc Re Canon, Stéphanie Henry, Esma Saada-Bouzid, Jean-Pascal H. Machiels
- Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406). (Abstract 2023)
Poster Session: Central Nervous, System Tumors
Time: Saturday, June 2, 2018, 1:15 PM – 4:45 PM
Authors: Martin J. Van Den Bent, Pim French, Marica Eoli, Juan M. Sepúlveda, Anna Maria Elisabeth Walenkamp, Jean-Sebastien Frenel, Enrico Franceschi, Paul M. Clement, Michael Weller, Iris de Heer, Jim Looman, Jyotirmoy Dey, Scott Krause, Hao Xiong, Peter J Ansell, Sarah Nuyens, Maarten Spruyt, Joana Brilhante, Thierry Gorlia, Vassilis Golfinopoulos
- A randomized doubled blind phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (DTC) progressing after first line therapy: EORTC 1209. (Abstract 6021)
Poster Discussion Session: Head and Neck Cancer
Time: Saturday, June 2, 2018, 4:45 – 6 PM
Authors: Martin Schlumberger, Kate Newbold, Baktiar Hasan, Sandrine Marreaud, Samson Assele, Lisa F. Licitra, Patrick Schoffski, Sophie Leboulleux, Laura Locati, Yann Godbert, Vincent Rohmer, Barbara Jarzab, Salvatore Domenico, Oliver Edgar Bechter, Sylvie Zanetta, Jaume Capdevila, Ellen Kapiteijn, Lars Bastholt
- EORTC-ESSO 1409 GITCG: A prospective colorectal liver metastasis database with an integrated quality assurance program (CLIMB). (Abstract 3558)
Poster Session: Gastrointestinal Cancer
Time: Sunday, June 3, 2018, 8:00 – 11:30 AM
Authors: Carmela Aves Caballero, Lucia Carrion Alvarez, Henrik Nilsson, Theo Ruers, Perrine Senellart, Michel Rivoire, Stefan Stattner, Florian Primavesi, Roberto Troisi, Thomas Gruenberger, Jan Heil, Andreas Schnitzbauer, Nuh N. Rahbari, Rutger-Jan Swijnenburg, Hassan Zakria Malik, Mladjan Protic, Anouk Neven, Murielle E. Mauer, Graeme John Poston, Serge Evrard
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023